Core Insights - Fortrea Holdings Inc. (NASDAQ:FTRE) is recognized as one of the most promising small-cap stocks by Wall Street analysts [1] - The company has provided financial guidance for 2026, projecting total revenues between $2,550 million and $2,650 million, with adjusted EBITDA expected to range from $190 million to $220 million [4][6] Financial Performance - For Q4 2025, Fortrea reported sales of $660.5 million, while the total sales for the entire year reached $2,723.4 million [5] - The company experienced a GAAP net loss of $(986.2) million, primarily due to a $797.9 million non-cash goodwill impairment, although adjusted net income was reported at $40.4 million [5] - The adjusted EBITDA for 2025 was $189.9 million, and the company ended the year with $174.6 million in cash and cash equivalents, alongside $1,066.3 million in gross debt [5] Market Position - Fortrea Holdings operates as a global contract research organization, providing a range of services including clinical development, trial management, pharmacology, and consulting to pharmaceutical, biotech, and medical device companies [7]
Fortrea Holdings Inc. (FTRE) 2026 Guidance Assumes Stable FX Rates from End-2025